Key facts
- It has raised $24.6M; the latest was Grant ($2.7M) in Aug 2024.
- Notable investors include European Commission, European Innovation Council (Belgium), Guangzhou Sino-Israel Bio-Industry Investment Fund, Horizon Europe, U.S. Navy — 6 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for CorNeat Vision
- ·The full record, as it builds
Funding rounds
No funding rounds for CorNeat Vision are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About CorNeat Vision
Developer of ophthalmic implants designed for surgical treatment of corneal blindness and ocular disorders. The company features bio-integrative materials, artificial corneas, glaucoma drainage devices, and scleral reinforcement patches, enabling ophthalmic surgeons and healthcare providers to restore vision, reduce immune rejection, and improve long-term outcomes for patients with severe corneal damage or degenerative eye conditions.
- Sector
- Healthcare
- HQ
- Raanana, Israel
- Founded
- 2015
- Employees
- 21
- Website
- corneat.com/
- Ownership
- Privately Held (backing)
CorNeat Vision doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in CorNeat Vision shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on CorNeat Vision in its N-PORT filings yet. We sweep new filings monthly.